Ray Therapeutics Appoints Christopher Whitmore as Chief Financial Officer
Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases
Ray Therapeutics to Present at Upcoming Scientific Conferences
Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing